Navitas stock soars as company advances 800V tech for NVIDIA AI platforms
Investing.com -- Sanofi’s experimental drug amlitelimab successfully met all primary endpoints in a Phase 3 clinical trial involving adolescent and adult patients with eczema, also known as atopic dermatitis.
The French pharmaceutical company announced Thursday that the drug demonstrated efficacy in skin clearance and disease severity compared to placebo.
According to Sanofi, the drug’s effectiveness increased progressively throughout the treatment period.
The company reported that amlitelimab was well tolerated by patients, with no new safety concerns identified during the study.
Sanofi stated that these positive results strengthen amlitelimab’s potential as a treatment for atopic dermatitis.
The company is currently conducting additional late-stage trials of the drug, which will form the basis for potential regulatory submissions worldwide.
Shares of Sanofi rose 1.91% following the announcement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.